Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

11 Jun 2026, 22:51 UTC · 1h ago

CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

4 claims · each scored for market impact

What matters in this story

1
CRISPR Therapeutics AG is projected to see quarterly revenue growth of 942.7% compared to the prior-year quarter. — Massive revenue growth indicates a significant commercial scale-up or new product launch, which is a primary driver for biotech valuations.
+0.60
2
Zacks Consensus EPS estimates for CRISPR Therapeutics AG have increased by 3.99% over the past month. — Positive analyst revisions generally correlate with near-term upward price movement.
+0.30
3
The Medical - Biomedical and Genetics industry is ranked in the bottom 38% of all industries according to Zacks. — Poor industry-wide ranking suggests systemic headwinds for companies within this specific biotech niche.
-0.20
4